MedTrace Logo

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

NCT01464827 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 580

Last updated 2015-04-22

Study results available
· View outcomes & findings →

Summary

This is a study of combination direct-acting antiviral agents (DAA) with or without ribavirin (RBV) in patients with chronic Hepatitis C Virus (HCV).

Conditions

  • Chronic Hepatitis C
  • Hepatitis C (HCV)
  • Hepatitis C Genotype 1

Interventions

DRUG

ABT-450

ABT-450 tablets

DRUG

ABT-333

ABT-333 tablets

DRUG

ABT-267

ABT-267 tablets

DRUG

Ribavirin

Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).

DRUG

Ritonavir

Ritonavir capsules

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Daniel Cohen, MD · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-03-31
Completion
2013-09-30

Countries

  • United States
  • Australia
  • Canada
  • France
  • Germany
  • New Zealand
  • Puerto Rico
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01464827 on ClinicalTrials.gov